Advertisement

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study

      Highlights

      • Celecoxib did not decrease the severity of CIN 3 as primary endpoint.
      • Serum VEGF levels might identify patients who may benefit from celecoxib.
      • Information provided on personalized chemoprevention trials for CIN 3

      Abstract

      Purpose

      To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers.

      Patients and methods

      Patients with CIN 3 were randomized to celecoxib 400 mg once daily (67 patients) or placebo (63 patients) for 14–18 weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha = 10% and 90% power when the treatment arm boosted the probability of success by 30%. Translational analysis included cervical tissue HPV genotyping, COX-2 expression in biopsies, and serum celecoxib and VEGF levels.

      Results

      In primary analysis, histologic regression was not significantly higher in the celecoxib group (40%) than in the placebo group (34.1%). However, exploratory analyses suggest patients with high serum VEGF levels exhibited greater regression in the celecoxib arm (47.3%) than in the placebo arm (14.3%). Regression rates were similar by treatment group in patients with low VEGF. VEGF levels increased over time in the placebo group, but remained the same in the treatment group. COX-2 expression in cervical biopsies declined from pre-treatment to the end of treatment with celecoxib; it did not change with placebo.

      Conclusions

      Celecoxib at 400 mg once daily for 14–18 weeks did not significantly decrease the severity of CIN 3 compared with placebo except, possibly, in subjects with high baseline VEGF. Therefore, serum VEGF levels might identify patients who may benefit from celecoxib or other therapies, personalizing future chemoprevention trials for CIN 3.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Soerjomataram I.
        • Dikshit R.
        • Eser S.
        • Mathers C.
        • Rebelo M.
        • et al.
        Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
        Int. J. Cancer. 2015; 136: E359-E386
        • Jin G.
        • LanLan Z.
        • Li C.
        • Dan Z.
        Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis.
        Arch. Gynecol. Obstet. 2014; 289: 85-99
        • Meyskens F.L.
        • Surwit E.
        • Moon T.E.
        • Childers J.M.
        • Davis J.R.
        • Dorr R.T.
        • et al.
        Enhancement of regression of CIN II with topically applied all-trans-retinoic acid: a randomized trial.
        J. Natl. Cancer Inst. 1994; 86: 539-543
        • Romney S.L.
        • Ho G.Y.
        • Palan P.R.
        • Basu J.
        • Kadish A.S.
        • Klein S.
        • et al.
        Effects of B-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection.
        Gynecol. Oncol. 1997; 65: 483-492
        • Vlastos A.T.
        • West L.A.
        • Atkinson E.N.
        • Boiko I.
        • Malpica A.
        • Hong W.K.
        • et al.
        Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3.
        Clin. Cancer Res. 2005; 11: 390-396
        • Bell M.C.
        • Crowley-Nowick P.
        • Bradlow H.L.
        • Sepkovic D.W.
        • Schmidt-Grimminger D.
        • Howell P.
        • et al.
        Placebo-controlled trial of indole-3-carbinol in the treatment of CIN.
        Gynecol. Oncol. 2000; 78: 123-129
        • Van Pachterbeke C.
        • Bucella D.
        • Rozenberg S.
        • Manigart Y.
        • Gilles C.
        • Larsimont D.
        • et al.
        Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study.
        Gynecol. Oncol. 2009; 115: 69-74
        • Grimm C.
        • Polterauer S.
        • Natter C.
        • Rahhal J.
        • Hefler L.
        • Tempfer C.B.
        • et al.
        Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial.
        Obstet. Gynecol. 2012; 120: 152-159
        • Farley J.H.
        • Truong V.
        • Goo E.
        • Uyehara C.
        • Belnap C.
        • Larsen W.I.
        A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia.
        Gynecol. Oncol. 2006; 103: 425-430
        • Ferrandina G.
        • Lauriola L.
        • Distefano M.G.
        • Zannoni G.F.
        • Gessi M.
        • Legge F.
        • et al.
        Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.
        J. Clin. Oncol. 2002; 20: 973-981
        • Kulkarni S.
        • Rader J.S.
        • Zhang F.
        • Liapis H.
        • Koki A.T.
        • Masferrer J.L.
        • et al.
        Cyclooxygenas-2 is overexpressed in human cervical cancer.
        Clin. Cancer Res. 2001; 7: 429-434
        • Wang D.
        • Dubois R.N.
        Eicosanoids and cancer.
        Nat. Rev. Cancer. 2010; 10: 181-193
        • Bertagnolli M.M.
        • Eagle C.J.
        • Zauber A.G.
        • et al.
        Celecoxib for the prevention of sporadic colorectal adenomas.
        N. Engl. J. Med. 2006; 355: 873-884
        • Elmets C.A.
        • Viner J.L.
        • Pentland A.P.
        • Cantrell W.
        • Lin H.Y.
        • Bailey H.
        • et al.
        Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
        J. Natl. Cancer Inst. 2010; 102: 1835-1844
        • Derosa L.
        • Galli L.
        • Orlandi P.
        • Fioravanti A.
        • Di Desidero T.
        • Fontana A.
        • et al.
        Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
        Cancer. 2014; 120: 3923-3931
        • Wei D.
        • Wang L.
        • He Y.
        • Xiong H.Q.
        • Abbruzzese J.L.
        • Xie K.
        Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
        Cancer Res. 2004; 64: 2030-2038
        • Xu X.
        • Jiang M.
        • Zhang Y.
        • Bi Y.
        • Han M.
        Celecoxib attenuates cachectic events in mice by modulating the expression of vascular endothelial growth factor.
        Mol. Med. Rep. 2015; 11: 289-294
        • Rosas C.
        • Sinning M.
        • Ferreira A.
        • Fuenzalida M.
        • Lemus D.
        Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy.
        Biol. Res. 2014; 47: 27
        • Sui W.
        • Zhang Y.
        • Wang Z.
        • Wang Z.
        • Jia Q.
        • Wu L.
        • et al.
        Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H(2)(2) murine hepatocarcinoma model.
        Oncol. Rep. 2014; 31: 2252-2260
        • Halamka M.
        • Cvek J.
        • Kubes J.
        • Zavadova E.
        • Kominek P.
        • Horacek J.
        • et al.
        Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.
        Oral Oncol. 2011; 47: 763-767
        • Zhu Y.M.
        • Azahri N.S.
        • Yu D.C.
        • Woll P.J.
        Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells.
        BMC Cancer. 2008; 8: 218
        • Mao J.T.
        • Roth M.D.
        • Fishbein M.C.
        • Aberle D.R.
        • Zhang Z.F.
        • Rao J.Y.
        • et al.
        Lung cancer chemoprevention with celecoxib in former smokers.
        Cancer Prev. Res. (Phila.). 2011; 4: 984-993
        • Gius D.
        • Funk M.C.
        • Chuang E.Y.
        • Feng S.
        • Huettner P.C.
        • Nguyen L.
        • et al.
        Profiling Microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates.
        Cancer Res. 2007; 67: 7113-7123
        • Smith-McCune K.
        • Zhu Y.H.
        • Hanahan D.
        • Arbeit J.
        Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice.
        Cancer Res. 1997; 57: 1294-1300
        • Smith-McCune K.K.
        • Weidner N.
        Demonstration and characterization of the angiogenic properties of cervical dysplasia.
        Cancer Res. 1994; 54: 800-804
        • Hammes L.S.
        • Tekmal R.R.
        • Naud P.
        • Edelweiss M.I.
        • Kirma N.
        • Valente P.T.
        • et al.
        Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.
        Gynecol. Oncol. 2008; 110: 445-451
        • Obermair A.
        • Bancher-Todesca D.
        • Bilgi S.
        • Kaider A.
        • Kohlberger P.
        • Mullauer-Ertl S.
        • et al.
        Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia.
        J. Natl. Cancer Inst. 1997; 89: 1212-1217
        • Hefler L.A.
        • Grimm C.
        • Speiser P.
        • Sliutz G.
        • Reinthaller A.
        The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II–III A phase II trial.
        Eur. J. Obstet. Gynecol. Reprod. Biol. 2006; 125: 251-254
        • Grabosch S.M.
        • Shariff O.M.
        • Wulff J.L.
        • Helm C.W.
        Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
        Cochrane Database Syst. Rev. 2014; 4CD004121
        • Alberts D.S.
        • Potter J.D.
        • Martinez M.E.
        • Hess L.M.
        • Stopeck A.
        • Lance P.
        What happened to the coxibs on the way to the cardiologist?.
        Cancer Epidemiol. Biomark. Prev. 2005; 14: 555-556
        • Brenner S.S.
        • Herrlinger C.
        • Dilger K.
        • Murdter T.E.
        • Hofmann U.
        • Marx C.
        • et al.
        Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.
        Clin. Pharmacokinet. 2003; 42: 283-292
        • Frank D.H.
        • Roe D.J.
        • Chow H.H.
        • Guillen J.M.
        • Choquette K.
        • Gracie D.
        • et al.
        Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial.
        Cancer Epidemiol. Biomark. Prev. 2004; 13: 299-303
        • Sauter E.R.
        • Qin W.
        • Hewett J.E.
        • Ruhlen R.L.
        • Flynn J.T.
        • Rottinghaus G.
        • et al.
        Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women.
        BMC Cancer. 2008; 8: 49
        • Kim E.S.
        • Hong W.K.
        • Lee J.J.
        • Mao L.
        • Morice R.C.
        • Liu D.D.
        • et al.
        Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
        Cancer Prev. Res. (Phila.). 2010; 3: 148-159
        • Steinbach G.
        • Lynch P.M.
        • Phillips R.K.
        • Wallace M.H.
        • Hawk E.
        • Gordon G.B.
        • et al.
        The effect of Celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis.
        N. Engl. J. Med. 2000; 342: 1946-1952
        • Wirth L.J.
        • Krane J.F.
        • Li Y.
        • Othus M.
        • Moran A.E.
        • Dorfman D.M.
        • et al.
        A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions.
        Cancer Prev. Res. (Phila.). 2008; 1: 339-348
        • Darragh T.M.
        • Colgan T.J.
        • Thomas Cox J.
        • Heller D.S.
        • Henry M.R.
        • Luff R.D.
        • et al.
        The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
        Int. J. Gynecol. Pathol. 2013; 32: 76-115